Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Kiniksa Pharmaceuticals International, plc (KNSA) vs Lantheus Holdings, Inc. (LNTH)

Kiniksa Pharmaceuticals International, plc and Lantheus Holdings, Inc. are both Drug Manufacturers Specialty & Generic companies. Lantheus Holdings, Inc. is the larger, with a market value of $6.5B against $5.9B — 1.1× the size. Lantheus Holdings, Inc. trades at the lower P/E: 23.7× against 70.2×. Kiniksa Pharmaceuticals International, plc grew revenue faster over the last twelve months: 58.9% against 2.35%. Lantheus Holdings, Inc. has the higher net margin (17.7% vs 9.59%) and the lower return on invested capital (14.7% vs 48.9%). Across the 20 metrics below, Lantheus Holdings, Inc. leads on 13 and Kiniksa Pharmaceuticals International, plc on 7.

Valuation

Metric KNSA LNTH Drug Manufacturers Specialty & Generic median
P/E 70.17 23.69 20.14
P/S 6.93 4.18 2.25
P/B 8.90 4.95 1.90
Price to free cash flow 31.84 16.54 16.54
EV/EBITDA 51.93 16.38 12.29
EV/Sales 6.30 4.16 2.56
Earnings yield 1.43% 4.22% (2.99%)
Free cash flow yield 3.14% 6.04% 0.00%

Profitability

Metric KNSA LNTH Drug Manufacturers Specialty & Generic median
Gross margin 89.82% 60.14% 53.94%
Operating margin 11.92% 19.43% 0.00%
Net margin 9.59% 17.69% 0.00%
Free cash flow margin 21.74% 25.24% 0.00%
Return on equity 14.04% 22.21% (0.40%)
Return on assets 10.36% 12.15% (3.32%)
Return on invested capital 48.87% 14.65% 0.00%

Growth

Metric KNSA LNTH Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 58.85% 2.35% 10.01%
EPS growth (last fiscal year) 225.00% (21.79%) —
Revenue growth, 5-year CAGR — 35.35% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric KNSA LNTH Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 0.44 0.05
Current ratio 3.90 3.06 2.31
Net debt to EBITDA (5.26) 0.55 0.85

Dividend

Metric KNSA LNTH Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric KNSA LNTH Drug Manufacturers Specialty & Generic median
Market cap 5.90b 6.51b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack